Supplemental Figure 3 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer
Year: 2023
Type: supplementary-materials
Abstract: The presence of the eight driver alterations highlighted in the manuscript is provided for each patient biopsy sample. These alterations include (alphabetically): AKT1 activation, AURKA amplification, biallelic RB1 disruption, CCNE2 amplification, ER loss (via IHC), ERBB2 activation, FGFR2 activation, and RAS activation (including HRAS, KRAS, and NRAS). For each biopsy specimen, the total number of potential driver alterations is tallied.
Authors: Seth A. Wander, Ofir Cohen, Xueqian Gong, Gabriela N. Johnson, Jorge E. Buendia-Buendia, Maxwell R. Lloyd, Dewey Kim, Flora Luo, Pingping Mao, Karla Helvie, Kailey J. Kowalski, Utthara Nayar, Adrienne G. Waks, Stephen H. Parsons, Ricardo Martinez, Lacey M. Litchfield, Xiang S. Ye, Chunping Yu, Valerie M. Jansen, John R. Stille, Patricia S. Smith, Gerard J. Oakley, Quincy S. Chu, Gerald Batist, Melissa E. Hughes, Jill D. Kremer, Levi A. Garraway, Eric P. Winer, Sara M. Tolaney, Nancy U. Lin, Sean G. Buchanan, Nikhil Wagle
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362539389